問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Shin Kong Memorial Wu Ho-Su Hospital (在職)

Division of Ophthalmology

更新時間：2023-09-19

鄭成國
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭成國

Shin Kong Memorial Wu Ho-Su Hospital

Division of Ophthalmology

List

10Cases

2025-11-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting4Sites

2009-08-01 - 2012-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2020-08-20 - 2024-08-07

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2010-01-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2020-05-01 - 2021-08-20

Phase III

To determine if treatment with aflibercept 8 mg (HD) at intervals of 12 or 16 weeks provides non-inferior BCVA change compared to aflibercept 2 mg every 8 weeks in participants with nAMD

  • Condition/Disease

    NAMD

  • Test Drug

    BAY 86-5321

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2018-06-04 - 2020-01-19

Phase III

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1)

  • Condition/Disease

    Age-Related Macular Degeneration (AMD)

  • Test Drug

    Conbercept

Participate Sites
5Sites

Recruiting5Sites

2014-04-30 - 2017-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2016-01-04 - 2019-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2017-09-01 - 2018-09-06

Phase III

SAPPHIRE: A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion

  • Condition/Disease

    subjects with retinal vein occlusion

  • Test Drug

    CLS-TA

Participate Sites
5Sites

Terminated4Sites

2013-09-03 - 2020-06-30

Phase I/II

A Phase I/II trial of TLC399 (ProDex) in Patients with Macular Edema due to Retinal Vein Occlusion (RVO): An Open-label, Sequential Dose Escalation Phase I Part to Determine Maximum Tolerated Dose (MTD) and Dose Limiting Toxicities (DLTs) Followed by a Single-masked, Randomized Part to Evaluate Efficacy and Tolerability

  • Condition/Disease

    Macular Edema due to Retinal Vein Occlusion (RVO)

  • Test Drug

    TLC399 (ProDex)

Participate Sites
7Sites

Terminated7Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB